Jyong Biotech (NASDAQ:MENS) Trading Up 15.1% – What’s Next?

Jyong Biotech Ltd. (NASDAQ:MENS) shares were up 15.1% on Monday . The stock traded as high as $31.32 and last traded at $31.32. Approximately 47,130 shares were traded during trading, a decline of 83% from the average daily volume of 284,691 shares. The stock had previously closed at $27.20.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Jyong Biotech Stock Performance

The business has a fifty day moving average of $45.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jyong Biotech stock. Millennium Management LLC bought a new stake in shares of Jyong Biotech Ltd. (NASDAQ:MENS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 13,013 shares of the company’s stock, valued at approximately $512,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.